28 June 2019 | News
A new, state-of-the-art clinical and niche commercial facility to support pharmaceutical and biotechnology companies throughout the development and manufacture of active pharmaceutical ingredients (API)
Image Courtesy: Conceptlifesciences
Concept Life Sciences, a knowledge-based provider of integrated discovery, development and analytical services, on 18 June 2019, unveiled a new, state-of-the-art clinical and niche commercial facility to support pharmaceutical and biotechnology companies throughout the development and manufacture of active pharmaceutical ingredients (API). Located at Discovery Park in Sandwich, UK, the purpose-built facility offers a comprehensive range of services designed to allow partner organizations to take drug candidates through discovery, scale up and into current Good Manufacturing Practice (cGMP)-compliant production.
“Pharmaceutical and biotech companies of all sizes are demanding high-quality, early-stage manufacturing capabilities that can readily scale up target molecules from grams to kilograms, and then into cGMP-compliant API manufacture all while mitigating the risk typically associated with moving between different stages of the drug development process,” said Dr Paul Doyle, Chief Scientific Officer at Concept Life Sciences. “Building on our depth of scientific expertise in medicinal and discovery chemistry, the new, specialist facility strengthens our support services so we can enable our partners to boost their productivity and deliver products to market faster and more efficiently.”
With the new facility joining the company’s growing network of sites across the UK, Concept Life Sciences’ pharmaceutical manufacturing support services now comprise: